TITLE

GENEREX PRESENTS POTENTIAL USES OF RAPIDMIST

PUB. DATE
August 2004
SOURCE
Biotech Equipment Update;Aug2004, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Generex Biotechnology Corp., Toronto, has presented a research abstract by Robert Humphreys, the chief scientific officer of its Antigen Express immunomedicines subsidiary, at the Foundation Merieux Conference, "Innate and Adaptive Immunity after Transcutaneous or Mucosal Vaccination." Pankaj Modi, the inventor of the technology at Generex, developed a novel method for aerosolized delivery of proteins and peptides through the buccal mucosa by a RapidMist device using a pressurized fluorocarbon. The administered insulin is absorbed rapidly and provides a therapeutic plasma level within 20 minutes of application.
ACCESSION #
13883140

 

Related Articles

  • Generex Biotechnology: vaccines a clear way ahead for RapidMist.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p50 

    Reports on chief scientific officer of Generex Biotechnology's Antigen Express immunomedicines subsidiary, Robert Humphreys' presentation of a research abstract at the Foundation Merieux Conference discussing the prospects for the company's RapidMist delivery system. Benefits of the technology...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5 

    The article deals with the interim data presented by Generex Biotechnology Corp. at the 2011 San Antonio Breast Cancer Symposium from its continuing Phase II study of the li-Key hybrid-based HER2/neu peptide vaccine in HER2-expressing breast cancer patients.

  • AACR Roundup.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8 

    The article focuses on the study data presented by Generex Biotechnology Corp. at the annual meeting of the American Association for Cancer Research (AACR) on the effect of a peptide vaccine on a subgroup of CD4-positive cells can suppress immune responses.

  • ASCO 2013.  // BioWorld Today;6/3/2013, Vol. 24 Issue 105, p7 

    The article discusses data for li-Key modified HER2 peptide vaccine presented by Generex Biotechnology Corp. at the American Society of Clinical Oncology (ASCO) meeting held in Chicago, Illinois in June 2013.

  • Gum to replace needles?  // Pharmaceutical Technology Europe;Feb2006, Vol. 18 Issue 2, p10 

    The article reports on Generex's development of a chewing gum as an alternative buccal drug delivery method for metformin, which is used for treating diabetes. Results from a small clinical trial suggest that the use of chewing gum could prevent gastrointestinal side-effects which usually...

  • Clinic Roundup.  // BioWorld Today;7/11/2011, Vol. 22 Issue 132, p5 

    This section offers news briefs on clinical trials as of July 11, 2011. Positive preliminary results were obtained by Generex Biotechnology Corp. from two clinical trials of diabetes drug candidate Generex Oral-lyn. Halozyme Therapeutics Inc. and Baxter International Inc. plan to support the...

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • Clinic Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p8 

    This section offers updates on biotechnology sector clinical progress as of May 23, 2013. Acelrx Pharmaceuticals Inc. reported on the results of a Phase III study with its Sufentanil NanoTab patient-controlled analgesia (PCA) system. Agenus Inc. announced the start of a Phase II study with a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics